Company type | Privately held company |
---|---|
Industry | |
Founded | January 2015 | in San Francisco, California, United States
Founders |
|
Headquarters | US |
Area served | Worldwide |
Website |
excision |
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University. [1] [2] [3] [4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status. [5] In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects but no data on its effectiveness was disclosed. [6]
Company type | Privately held company |
---|---|
Industry | |
Founded | January 2015 | in San Francisco, California, United States
Founders |
|
Headquarters | US |
Area served | Worldwide |
Website |
excision |
Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University. [1] [2] [3] [4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status. [5] In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects but no data on its effectiveness was disclosed. [6]